Eli Lilly & Co. (LLY): Expert Call Supports Amyloid Hypothesis of AD - BMO

October 3, 2016 7:21 AM EDT
Get Alerts LLY Hot Sheet
Price: $76.76 --0%

Rating Summary:
    20 Buy, 5 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 18 | Down: 20 | New: 8
Trade LLY Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

BMO Capital analyst, Alex Arfaei, reiterated his Outperform rating on shares of Eli Lilly (NYSE: LLY) after an expert call highlighted that the evidence supporting the amyloid hypothesis of AD outweighs the evidence that undercuts it.

The expert highlighted plausible explanations that could explain the observed discrepancies, explained why ADAS-Cog-14 is an appropriate endpoint in mild AD, and estimated that Lilly's EXPEDITION-3 trial has a ~60% probability of success.

The expert believes that the future is probably combination therapy, focusing on different drivers of AD (e.g., AB and Tau) and varying by disease stage. He believes that Sola's excellent safety profile makes it an attractive option for combinations.

No change to the price target of $94.

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $80.26 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

BMO Capital

Add Your Comment